Mirtazapine is the More Appropriate First-Line Treatment
For this 78-year-old man with post-hip fracture depression complicated by anorexia and weight loss, mirtazapine is strongly preferred over duloxetine as the first-line antidepressant. The patient's clinical presentation—specifically the anorexia and weight loss—makes mirtazapine's side effect profile therapeutically advantageous rather than problematic.
Rationale for Mirtazapine
Weight Gain and Appetite Stimulation as Therapeutic Benefits
Mirtazapine's propensity for weight gain, typically considered an adverse effect, becomes a therapeutic asset in this context. In controlled trials, 17% of patients on mirtazapine experienced appetite increase (vs. 2% on placebo), and 7.5% gained ≥7% of body weight (vs. 0% on placebo) 1. This weight-gaining property has been specifically studied in underweight older adults, where mirtazapine has demonstrated effectiveness in stimulating appetite and promoting weight gain 2, 3.
Safety Profile in Older Adults
Mirtazapine is specifically recommended as a preferred agent for older patients with depression 4. Unlike duloxetine, mirtazapine lacks significant anticholinergic effects, does not cause clinically meaningful cardiac conduction abnormalities, and has a more favorable cardiovascular profile—critical considerations in a 78-year-old post-fracture patient who may have underlying cardiovascular disease or be at risk for falls.
Sedation as a Potential Benefit
While 54% of patients experience somnolence with mirtazapine 1, this sedating effect can be beneficial in older adults with depression who often experience insomnia and agitation. The sedation typically occurs at lower doses (7.5-15 mg), with paradoxically less sedation at higher doses (30-45 mg) due to increased noradrenergic activity.
Why Not Duloxetine in This Case
Nausea and Weight Loss Risk
Duloxetine's most common adverse effect is nausea 5, which occurs frequently enough that dosing protocols recommend starting at 30 mg for one week before increasing to 60 mg to mitigate this effect. In a patient already experiencing anorexia and weight loss, introducing a medication that commonly causes nausea is counterproductive and could worsen nutritional status.
Limited Evidence for Weight Gain
While duloxetine has established efficacy for depression and certain pain conditions 5, 6, it does not offer the appetite-stimulating or weight-promoting effects needed in this clinical scenario. In fact, among antidepressants studied for weight effects, duloxetine showed modest weight gain (0.34 kg more than sertraline at 6 months) 7, far less than mirtazapine's effect.
Fracture Risk Considerations
Recent evidence suggests that duloxetine may be associated with higher fracture risk in older adults compared to mirtazapine 8. In a large case-control study, duloxetine showed an adjusted odds ratio of 1.54 for non-vertebral fractures, while mirtazapine (used as the reference comparator) had the lowest risk profile among antidepressants studied. This is particularly relevant in a patient recovering from hip fracture.
Practical Prescribing Approach
Start mirtazapine at 7.5-15 mg at bedtime, utilizing the sedating effect to address any sleep disturbance. The lower starting dose minimizes excessive sedation while still providing appetite stimulation. Titrate to 30 mg after 1-2 weeks if tolerated, as this dose provides robust antidepressant effects with continued appetite benefits but less daytime sedation.
Monitor weight weekly during the first month, with a target of stabilizing or reversing weight loss. The antidepressant effect typically emerges within 2-4 weeks, while appetite improvement may occur earlier.
Important Caveats
Avoid mirtazapine if the patient has:
- Known QT prolongation or significant cardiac arrhythmias (though risk is lower than with many alternatives) 1
- History of agranulocytosis or severe bone marrow suppression
- Concurrent use of MAOIs 1
Monitor for:
- Excessive sedation leading to fall risk (though evidence suggests lower fracture risk than other antidepressants) 8
- Hyponatremia, particularly given age and post-surgical status 1
- Cholesterol and triglyceride elevations with long-term use 1
The combination of depression treatment, appetite stimulation, and weight gain makes mirtazapine uniquely suited for this clinical presentation, while duloxetine's nausea profile and lack of weight-promoting effects make it a poor choice despite its established antidepressant efficacy.